Coordinated selling by multiple C-suite executives, especially the CFO, signals potential lack of confidence in near-term prospects. Traders should monitor upcoming earnings, pipeline updates, or clinical trial data for downward revisions or delays that may not yet be public.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 25 $98.00entry
- T+1 · 8mo ago +0.06%α +1.83% · $98.06
- T+5 · 8mo ago +7.80%α +8.04% · $105.64
- T+20 · 7mo ago +10.22%α +2.36% · $108.02
- T+60 · 5mo ago +25.94%α +12.49% · $123.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite executives at Nuvalent sold a combined $1.71M in shares over a 7-day period, including CFO Alexandra Balcom who sold $1.37M, the largest individual transaction. These were open-market sales, not tax-related or non-cash events, and represent a coordinated exit by senior insiders.
Key Financial Metrics
Key Facts
- CFO Alexandra Balcom sold 13,700 shares for $1.37M at $100.16 per share on March 25, 2026
- Chief Development Officer Darlene Noci sold 2,532 shares for $246,693 at $97.43 on March 30, 2026
- Chief Legal Officer Deborah Miller sold 940 shares for $91,650 at $97.50 on March 26, 2026
- Total open-market sales: $1.71M across three C-suite executives in seven days
- Non-cash derivative exercises also occurred but are not economically significant
Financial Impact
$1.71M in insider selling by C-suite executives, representing 0.021% of Nuvalent's $8.1B market cap
Risk Factors
- Insider selling may precede negative news such as clinical trial setbacks or funding challenges
- Perception of weakening leadership confidence could pressure stock despite small absolute size of sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NUVL-1775075501840 |
Track record
18 reports on NUVL
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 7 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers